Abbvie Inc.

Other

Abbott Laboratories Corporation

Abbvie Bahamas Limited

Maria A Argiriadi

Richard W Dixon

Michael M Friedman

Yan Chen

Shankar Kumar

Kristine E Frank

Chengbin Wu

Paul Robert Hinton

Eric C Breinlinger

Jonathan P Belk

Hua Ying

Carolyn A Cuff

Terry L Melim

Anna M Ericsson

David J Calderwood

Neil Wishart

Biqin C Li

Lu Wang

Dawn M George

Michael Morytko

Kelly Mullen

Kevin Patrick Cusack

Kent D Stewart

Kevin R Woller

Adrian Hobson

Grier A Wallace

Shuhui Chen

Marlon D Cowart

Chung-Ming Hsieh

Martine Barth

Michael Z Hoemann

Jeffrey W Voss

Michael L Friedman

Michael R Schrimpf

Michael E Kort

Thomas D Gordon

Wentao Wu

Huaqing Liu

Lorenzo Benatuil

Marc J Scanio

Jianfei Wang

Noel S Wilson

Justin D Dietrich

David Wayne Borhani

Augustine Osuma

Gillian A Kingsbury

Robert V Talanian

Andrew Burchat

Didier Thomas

David Ihle

Bradford L McRae

Nathan Josephsohn

Bryan A Fiamengo

Michael J Morytko

Dominique Bonafoux

Xiaoyun Wu

Fabrice Guillier

Gagandeep K Somal

John E Harlan

Eric R Goedken

Dominique Potin

J Martin Herold

Claude E Barberis

James Patrick Stambuli

David Andrew Kinsman

Jerome Amaudrut

Rui Wang

Nathan S Josephsohn

Stacy A Van Epps

Matthew H Katcher

Linlin Dai

Jeremy Edmunds

Lily K Abbott

Xiaolei Zhang

Ellen Yulin Tsai Chien

Russell A Judge

David A Egan

Ciaran O'Reilly

Hannah Dexter

David J Hardee

Sami Osman

Euan Fordyce

Gloria Y LoSchiavo

Steve St Gallay

Jérôme Amaudrut

Wei Qiu

Olivia Poupardin

Laurent Mounier

Kangwen Deng

Thomas R Vargo

Denise Karaoglu Hanzatian

Matthew P Webster

Andrew J Little

Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, useful as RIPK1 inhibitors, and pharmaceutical compositions comprising same. Further provided are methods of use and preparation. Also provided are methods of treating Ulcerative Colitis using a compound of Formula (I).

Nicotinamide RIPK1 inhibitors

The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.

Interleukin-13 binding proteins

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R2, R, R, R, X, X, X, X, X, nad n are as defined herein, pharmaeceutical compositions 2C X, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use. 

Inhibitors of tyrosine kinase 2 mediated signaling

The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.

Indazolones as modulators of tnf signaling

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

Nuclear receptor modulators

The disclosure provides binding proteins that specifically bind to LRP-8 and optionally cross the blood brain barrier (BBB), localize to the brain and/or localize to the spinal cord.

LRP-8 binding dual variable domain immunoglobulin proteins

The invention provide a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomer and isomer thereof wherein the variable are defined herein. The compound of the invention are useful for treating immunological and oncological conditions.

Tricyclic compounds

The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof

The invention provides a compound of Formula (Ie), 

Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof

Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

Indazole compounds

Growing community of inventors

Wayland, MA, United States of America

Maria A Argiriadi